Treatment of severe sepsis with artemether-lumefantrine is associated with decreased mortality in ugandan patients without malaria

American Journal of Tropical Medicine and Hygiene

Volumn 80, Issue 5, 2009, Pages 723-728

  Moore, Christopher C ^a,b,c,d,e,f   Jacob, Shevin T ^a,b,c,d,e,f   Pinkerton, Relana ^a,b,c,d,e,f   Banura, Patrick ^a,b,c,d,e,f   Meya, David B ^{a,b,c,d,e,f,g}   Reynolds, Steven J ^a,b,c,d,e,f   Kenya Mugisha, Nathan ^{a,b,c,d,e,f,h}   Mayanja Kizza, Harriet ^{a,b,c,d,e,f,g}   Scheld, W Michael ^a,b,c,d,e,f  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Masaka Regional Referral Hospital   (Uganda)

^d MAKERERE UNIVERSITY   (Uganda)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^h MINISTRY OF HEALTH   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; FANSIDAR; QUININE; ANTIINFECTIVE AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; BENFLUMETOL; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ETHICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREVALENCE; PROSPECTIVE STUDY; SEPSIS; UGANDA; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED;

MURINAE;

ADULT; ANTI-INFECTIVE AGENTS; ARTEMISININS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; UGANDA; YOUNG ADULT;

EID: 66149086928     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.80.723     Document Type: Article

References (27)

1. Bone RC, Balk R A, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sep-sis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
2. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, 2003. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 168:165-172.
3. Ssali FN, Kamya MR, Wabwire-Mangen F, Kasasa S, Joloba M, Williams D, Mugerwa RD, Ellner JJ, Johnson JL, 1998. A pro-spective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol 19: 484-489.
4. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, Whitty CJ, 2007. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ 334: 403.
5. Hamer DH, Ndhlovu M, Zurovac D, Fox M, Yeboah-Antwi K, Chanda P, Sipilinyambe N, Simon JL, Snow RW, 2007. Improved diagnostic testing and malaria treatment practices in Zambia. JAMA 297:2227-2231.
6. Hill PC, Onyeama CO, Ikumapayi UN, Secka O, Ameyaw S, Simmonds N, Donkor SA, Howie SR, Tapgun M, Corrah T, Adegbola RA, 2007. Bacteraemia in patients admitted to an urban hospital in West Africa. BMC Infect Dis 7: 2.
7. Evans JA, Adusei A, Timmann C, May J, Mack D, Agbenyega T, Horstmann RD, Frimpong E, 2004. High mortality of infant bacteraemia clinically indistinguishable from severe malaria. QJM 97: 591-597.
8. Bronzan RN, Taylor TE, Mwenechanya J, Tembo M, Kayira K, Bwanaisa L, Njobvu A, Kondowe W, Chalira C, Walsh AL, Phiri A, Wilson LK, Molyneux ME, Graham SM, 2007. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 195: 895-904.
9. Berkley J, Mwarumba S, Bramham K, Lowe B, Marsh K, 1999. Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg 93:283-286.
10. WHO, 2006. Guidelines for the Treatment of Malaria/World Health Organization.
11. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, Ouedraogo JB, 2007. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin- piperaquine for the treatment of uncompli-cated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45:1453-1461.
12. Rulisa S, Gatarayiha JP, Kabarisa T, Ndayisaba G, 2007. Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine versus artesunate plus sulfamethoxypyrazine/pyrimethamine. Am J Trop Med Hyg 77: 612-616.
13. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ, 2007. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 297: 2210-2219.
14. Pareek A, Nandy A, Kochar D, Patel KH, Mishra SK, Mathur PC, 2006. Efficacy and safety of beta-arteether and alpha/beta-arteether for treatment of acute Plasmodium falciparum malaria. Am J Trop Med Hyg 75:139-142.
15. Health UMo, 2005. National Policy on Malaria Treatment. Available at: http.//www.health.go.ug/mcp/mt.html.
16. Wang J, Zhou H, Zheng J, Cheng J, Liu W, Ding G. Wang L, Luo P, Lu Y, Cao H, Yu S, Li B, Zhang L, 2006. The antima-larial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflam-matory cytokine release. Antimicrob Agents Chemother 50: 2420-2427.
17. Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Lian F, Sun L, 2007. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheu-matoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 46: 920-926.
18. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT, 2007. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11: R49.
19. Clark I A, Budd AC, Alleva LM, Cowden WB, 2006. Human malar-ial disease: a consequence of inflammatory cytokine release. Malar J 5: 85.
20. Zeni F, Freeman B, Natanson C, 1997. Anti-inflammatory thera-pies to treat sepsis and septic shock: a reassessment. Crit Care Med 25:1095-1100.
21. van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, Memming H, Frenkel J, Enwere G, Bennett S, Kwiatkowski D, Greenwood B, 1996. The effect of a monoclo-nal antibody to tumor necrosis factor on survival from child-hood cerebral malaria. J Infect Dis 174:1091-1097.
22. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D, 2003. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett 552:141-144.
23. Dondorp AM, Lee SJ, Faiz MA, Mishra S, Price R, Tjitra E, Than M, Htut Y, Mohanty S, Yunus EB, Rahman R, Nosten F, Anstey NM, Day NP, White NJ, 2008. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 47:151-157.
24. Zurovac D, Midia B, Ochola SA, English M, Snow RW, 2006. Microscopy and outpatient malaria case management among older children and adults in Kenya. Trop Med Int Health 11: 432-440.
25. Amexo M, Tolhurst R, Barnish G, Bates I, 2004. Malaria misdiag-nosis: effects on the poor and vulnerable. Lancet 364: 1896-1898.
26. Cheng AC, West TE, Limmathurotsakul D, Peacock SJ, 2008. Strategies to reduce mortality from bacterial sepsis in adults in developing countries. PLoS Med 5: el75.
27. Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA, 2006. Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis 42: 377-382.